Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
BACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.
Saved in:
Main Authors: | J Jones, R Panaccione, ML Russell, R Hilsden |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2011/837847 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Survey of Perceptions and Practices among Canadian Gastroenterologists regarding the Prevention of Venous Thromboembolism for Hospitalized Inflammatory Bowel Disease Patients
by: Roshan Razik, et al.
Published: (2012-01-01) -
The Approach to Dysplasia Surveillance in Inflammatory Bowel Disease
by: Remo Panaccione
Published: (2006-01-01) -
A Survey of Perceptions and Practices of Complementary Alternative Medicine among Canadian Gastroenterologists
by: Zane Gallinger, et al.
Published: (2014-01-01) -
Ophthalmological manifestations in inflammatory bowel disease under the watchful eye of a gastroenterologist from a tertiary centre
by: Konrad Lewandowski, et al.
Published: (2024-11-01) -
A Survey of Canadian Gastroenterologists about the Use of Methotrexate in Patients with Crohn’s Disease
by: Nilesh Chande, et al.
Published: (2005-01-01)